Skip to main content
Fig. 1 | Journal of Medical Case Reports

Fig. 1

From: Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

Fig. 1

Treatment with LCAR-B38M CAR-T cell therapy resulted in rapid λ light chain decline. Patient’s λ light chain levels (mg/L) prior to receiving LCAR-B38M CAR-T cells and throughout long-term follow-up to October 2020. CAR, chimeric antigen receptor; CR, complete response; DCEP, cisplatin, etoposide, ifosfamide, and dexamethasone; IFE, immunofixation; MRD, minimal residual disease; QD, once daily; RCD, lenalidomide, cyclophosphamide, and dexamethasone; VAD, vinorelbine, pirarubicin, and dexamethasone

Back to article page

Journal of Medical Case Reports

ISSN: 1752-1947